Timber Pharmaceuticals, Inc. (TMBR): Price and Financial Metrics
GET POWR RATINGS... FREE!
TMBR Stock Summary
- TIMBER PHARMACEUTICALS INC's market capitalization of $6,774,881 is ahead of merely 1.56% of US-listed equities.
- In terms of volatility of its share price, TMBR is more volatile than 98.92% of stocks we're observing.
- TIMBER PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -235.22%, greater than the shareholder yield of just 2.23% of stocks in our set.
- Stocks that are quantitatively similar to TMBR, based on their financial statements, market capitalization, and price volatility, are VBLT, IMGN, ATNM, DARE, and BLDP.
- Visit TMBR's SEC page to see the company's official filings. To visit the company's web site, go to www.timberpharma.com.
TMBR Valuation Summary
- TMBR's price/earnings ratio is -0.3; this is 101.36% lower than that of the median Healthcare stock.
- TMBR's EV/EBIT ratio has moved up 11.5 over the prior 93 months.
Below are key valuation metrics over time for TMBR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TMBR | 2023-01-30 | 23.1 | 0.8 | -0.3 | 0.2 |
| TMBR | 2023-01-27 | 23.4 | 0.8 | -0.3 | 0.2 |
| TMBR | 2023-01-26 | 23.1 | 0.8 | -0.3 | 0.2 |
| TMBR | 2023-01-25 | 23.4 | 0.8 | -0.3 | 0.2 |
| TMBR | 2023-01-24 | 24.2 | 0.9 | -0.4 | 0.2 |
| TMBR | 2023-01-23 | 23.4 | 0.8 | -0.3 | 0.2 |
TMBR Stock Price Chart Interactive Chart >
TMBR Price/Volume Stats
| Current price | $2.28 | 52-week high | $20.52 |
| Prev. close | $2.35 | 52-week low | $1.20 |
| Day low | $2.20 | Volume | 48,500 |
| Day high | $2.36 | Avg. volume | 140,567 |
| 50-day MA | $1.78 | Dividend yield | N/A |
| 200-day MA | $7.47 | Market Cap | 6.68M |
Timber Pharmaceuticals, Inc. (TMBR) Company Bio
Timber Pharmaceuticals, Inc. operates as a biotech company. The Company develops treatments for rare skin diseases. Timber Pharmaceuticals serves customers in the State of New Jersey.
Latest TMBR News From Around the Web
Below are the latest news stories about TIMBER PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TMBR as an investment opportunity.
Timber Pharmaceuticals to Host Investor Business Briefing: Milestone Achievements and Forward OutlookVirtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced it will host a virtual investor Business Briefing with Q&A on December 20, 2022, at 10:30 am ET. John Koconis, Ch |
Timber Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsBASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Company has received formal notice from The NYSE American LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing s |
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments f |
Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock SplitBASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, announced today that it will effect a 1-for-50 reverse stock split of its outstanding common stock. Subject to NYSE American (“NYSE” or the “Exchange”) approval, the Company anticipates that trading |
Timber Pharmaceuticals Announces Halt of Common Stock TradingCompliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced th |
TMBR Price Returns
| 1-mo | 3.17% |
| 3-mo | 49.02% |
| 6-mo | -69.60% |
| 1-year | -87.18% |
| 3-year | -99.07% |
| 5-year | -99.92% |
| YTD | 30.29% |
| 2022 | -90.79% |
| 2021 | -48.86% |
| 2020 | -85.40% |
| 2019 | -84.58% |
| 2018 | 0.00% |
Loading social stream, please wait...